CEO Paul Peter Tak was paid $5,344,561 in fiscal year 2025 (SEC filing 0001193125-26-191506 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,344,561 Paul Peter Tak total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CADL's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Peter Tak | $743,592 | $0 | $0 | $3,916,028 | $396,653 | $0 | $288,289 | $5,344,561 |
| Chief Executive Officer, President and Director | ||||||||
| Francesca Barone | 483,312 | 0 | 0 | 857,797 | 206,427 | 0 | 14,000 | 1,561,536 |
| Chief Scientific Officer | ||||||||
| Charles Schoch | 398,500 | 0 | 0 | 826,465 | 232,320 | 0 | 13,532 | 1,470,817 |
| Chief Financial Officer, Treasurer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Peter Tak | $5,344,561 | — | — | — |
| Francesca Barone | 1,561,536 | 726,222 | 706,876 | ↑ +835,314 |
| Charles Schoch | 1,470,817 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Candel Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CADL reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CADL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CADL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Christopher Martell | Independent Director | $114,546 |
| Edward J. Benz Jr., M.D | Independent Director | $103,546 |
| Gary J. Nabel, M.D., Ph.D | Independent Director | $99,546 |
| Joseph C. Papa, R.Ph., M.B.A | Independent Director | $101,810 |
| Maha Radhakrishnan, M.D | Independent Director | $158,346 |
| Nicoletta Loggia, Ph.D., R.Ph | Independent Director | $107,019 |
| Paul B. Manning | Independent Director | $130,546 |
| Paul Peter Tak, M.D., Ph.D., FMedSci | Director | — |
| Renee Gaeta | Independent Director | $103,046 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Peter Tak | Option | 6,875 | 4.12 | — |
| Paul Peter Tak | Option | 20,000 | 1.29 | — |
| Paul Peter Tak | Option | 415,625 | 8.55 | — |
| Francesca Barone | Option | 1,667 | 4.06 | — |
| Francesca Barone | Option | 2,292 | 4.12 | — |
| Francesca Barone | Option | 30,000 | 1.29 | — |
| Francesca Barone | Option | 91,042 | 8.55 | — |
| Charles Schoch | Option | 13,166 | 1.29 | — |
| Charles Schoch | Option | 65,709 | 8.55 | — |
| Charles Schoch | Option | 50,000 | 4.75 | — |
The executive compensation program is based on a pay-for-performance philosophy. Compensation is composed primarily of base salary, bonus, and equity incentives (stock options and RSUs) to align interests with stockholders and promote retention.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon company |
| Clawback policy | The company maintains a compensation recovery policy (clawback policy) in accordance with SEC and Nasdaq listing rules, requiring the recovery of incentive-based compensation in the event of a financial restatement due to material noncompliance. |
| Anti-hedging | The insider trading policy expressly prohibits short sales, derivative transactions, and hedging transactions with respect to the Company's securities by executive officers, directors, and employees. |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-23 | — | — | — | — | — |
| 2025 | 2025-06-17 | — | — | — | — | — |
| 2024 | 2024-06-26 | — | — | — | — | — |
| 2023 | 2023-06-28 | — | — | — | — | — |
| 2022 | 2022-10-13 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-23 | —a |
| 2025 | 2025-06-17 | —b |
| 2024 | 2024-06-26 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maha Radhakrishnan, M.DIndependent · Audit | $20,096 | $0 | $138,250 | — | $0 | $158,346 |
| Paul B. ManningIndependent · Compensation | 70,000 | 0 | 60,546 | — | 0 | 130,546 |
| Christopher MartellIndependent · Nominating/Governance | 54,000 | 0 | 60,546 | — | 0 | 114,546 |
| Nicoletta Loggia, Ph.D., R.PhIndependent · Compensation (Chair) · Nominating/Governance · Audit | 46,473 | 0 | 60,546 | — | 0 | 107,019 |
| Edward J. Benz Jr., M.DIndependent · Nominating/Governance (Chair) | 43,000 | 0 | 60,546 | — | 0 | 103,546 |
| Renee GaetaIndependent · Audit (Chair) | 42,500 | 0 | 60,546 | — | 0 | 103,046 |
| Joseph C. Papa, R.Ph., M.B.AIndependent · Compensation | 41,264 | 0 | 60,546 | — | 0 | 101,810 |
| Gary J. Nabel, M.D., Ph.DIndependent · Nominating/Governance | 39,000 | 0 | 60,546 | — | 0 | 99,546 |
| Paul Peter Tak, M.D., Ph.D., FMedSciEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $356,333 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $356,333 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Candel Therapeutics | 2025 | Paul Peter Tak | $743,592 | $0 | $3,916,028 | $396,653 | $5,344,561 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Paul Peter Tak | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 5,344,561. Filing ↗machine: r2 · c33 · span 520483–520492 |
| 2 | Section 01, Francesca Barone | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 1,561,536. Filing ↗machine: r4 · c33 · span 544904–544913 |
| 3 | Section 01, Charles Schoch | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Executive Compensation”. As printed: 1,470,817. Filing ↗machine: r6 · c33 · span 569302–569311 |
| 4 | Section 08, Maha Radhakrishnan, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 158,346. Filing ↗machine: span 383063–383272 |
| 5 | Section 08, Paul B. Manning | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 130,546. Filing ↗machine: span 335178–335387 |
| 6 | Section 08, Christopher Martell | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 114,546. Filing ↗machine: span 359111–359320 |
| 7 | Section 08, Nicoletta Loggia, Ph.D., R.Ph | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 107,019. Filing ↗machine: span 353130–353339 |
| 8 | Section 08, Edward J. Benz Jr., M.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 103,546. Filing ↗machine: span 341165–341374 |
| 9 | Section 08, Renee Gaeta | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 103,046. Filing ↗machine: span 347138–347347 |
| 10 | Section 08, Joseph C. Papa, R.Ph., M.B.A | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 101,810. Filing ↗machine: span 377076–377285 |
| 11 | Section 08, Gary J. Nabel, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 99,546. Filing ↗machine: span 365099–365307 |
| 12 | Section 08, Paul Peter Tak, M.D., Ph.D., FMedSci | DEF 14A | 2026-04-29 | 0001193125-26-191506 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 06, 2026 vote | Form 8-K | 2026-06-24 | 0001841387-26-000009 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0000950170-25-087696 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 06, 2024 vote | Form 8-K | 2024-06-28 | 0000950170-24-078795 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 356,333 + equity 0 + all other 0 = 356,333, summed across the director compensation table rows.machine: formula: Σ = 356,333 |
| 18 | Candel Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191506 | CEO total compensation as printed in Candel Therapeutics's own proxy. As printed: 5,344,561. Filing ↗machine: r2 · c33 · span 520483–520492 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
We'll email you a link to confirm.